MHC class I antigen processing regulated by cytosolic proteolysis - short cuts that alter peptide generation

被引:32
作者
Kessler, BM
Glas, R
Ploegh, HL
机构
[1] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA
[2] MTC, Karolinska Inst, S-17177 Stockholm, Sweden
关键词
cytosolic proteolysis; proteasome inhibitor; MNC class I antigens; cytotoxic T lymphocytes; tumor-associated antigens; oligopeptidases;
D O I
10.1016/S0161-5890(02)00100-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cytotoxic T lymphocyte (CTL)-mediated immune responses rely on the efficiency of MHC class I ligand generation and presentation by antigen presenting cells (APCs). Whereas the abnormal expression of MHC molecules and transporters associated with antigen processing (TAPs) are commonly discussed as factors that modulate antigen presentation, much less is known about possible regulatory mechanisms at the level of proteolysis responsible for the generation of antigenic peptides. The ubiquitin-proteasome system is recognized as the major component responsible for this process in the cytosol and its activity can be regulated by cytokines, such as IFN-gamma. However, new evidence suggests the involvement of other proteases that can contribute to cytosolic proteolysis and therefore, to the quality and quantity of antigen production. Here, we review recent findings on an increasing number of proteolytic enzymes linked to antigen presentation, and we discuss how regulation of cytosolic protease activities might have implications for immune escape mechanisms that could be used by tumor cells and pathogens. (C) 2002 Published by Elsevier Science Ltd.
引用
收藏
页码:171 / 179
页数:9
相关论文
共 104 条
[71]   Effects on NF-kappa B1/p105 processing of the interaction between the HTLV-1 transactivator tax and the proteasome [J].
Rousset, R ;
Desbois, C ;
Bantignies, F ;
Jalinot, P .
NATURE, 1996, 381 (6580) :328-331
[72]   Major histocompatibility complex class I-presented antigenic peptides are degraded in cytosolic extracts primarily by thimet oligopeptidase [J].
Saric, T ;
Beninga, J ;
Graef, CI ;
Akopian, TN ;
Rock, KL ;
Goldberg, AL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (39) :36474-36481
[73]   Perfect use of imperfection [J].
Schild, H ;
Rammensee, HG .
NATURE, 2000, 404 (6779) :709-710
[74]   Inactivation of a defined active site in the mouse 20S proteasome complex enhances major histocompatibility complex class I antigen presentation of a murine cytomegalovirus protein [J].
Schmidtke, G ;
Eggers, M ;
Ruppert, T ;
Groettrup, M ;
Koszinowski, UH ;
Kloetzel, PM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (10) :1641-1646
[75]   The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses [J].
Schwarz, K ;
de Giuli, R ;
Schmidtke, G ;
Kostka, S ;
van den Broek, M ;
Kim, KP ;
Crews, CM ;
Kraft, R ;
Groettrup, M .
JOURNAL OF IMMUNOLOGY, 2000, 164 (12) :6147-6157
[76]  
Schwarz K, 2000, EUR J IMMUNOL, V30, P3672, DOI 10.1002/1521-4141(200012)30:12<3672::AID-IMMU3672>3.0.CO
[77]  
2-B
[78]   HIV-1 Tat inhibits the 20 S proteasome and its 11 S regulator-mediated activation [J].
Seeger, M ;
Ferrell, K ;
Frank, R ;
Dubiel, W .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (13) :8145-8148
[79]   Antigen-processing machinery breakdown and tumor growth [J].
Seliger, B ;
Maeurer, MJ ;
Ferrone, S .
IMMUNOLOGY TODAY, 2000, 21 (09) :455-464
[80]   ER aminopeptidases generate a unique pool of peptides for MHC class I molecules [J].
Serwold, T ;
Gaw, S ;
Shastri, N .
NATURE IMMUNOLOGY, 2001, 2 (07) :644-651